Cogent Biosciences Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Cogent Biosciences, Inc. (Nasdaq: COGT) has announced its participation in two upcoming virtual investor conferences. The first is the 22nd Annual Needham Healthcare Conference scheduled for April 19, 2023, at 2:15 p.m. ET. The second event is the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 12:30 p.m. ET. Investors can access live webcasts of these conferences on Cogent's Investors & Media page, with replays available within two hours after each event, lasting for 30 days. Cogent, based in Waltham, MA, and Boulder, CO, focuses on precision therapies for genetically defined diseases, with bezuclastinib being its advanced clinical program targeting specific mutations linked to serious conditions like systemic mastocytosis and gastrointestinal stromal tumors.

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

• 22^nd Annual Needham Healthcare Conference
  Wednesday, April 19, 2023 at 2:15 p.m. ET

• Stifel 2023 Targeted Oncology Days
  Tuesday, April 25, 2023 at 12:30 p.m. ET
  

A live webcast of each event can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

What are the dates for the upcoming Cogent Biosciences investor conferences?

Cogent Biosciences will participate in the 22nd Annual Needham Healthcare Conference on April 19, 2023, and the Stifel 2023 Targeted Oncology Days on April 25, 2023.

How can investors access the Cogent Biosciences conference webcasts?

Investors can access the live webcasts of Cogent's conferences on the Investors & Media page of their website.

What is the focus of Cogent Biosciences' research?

Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, particularly targeting mutations associated with conditions like systemic mastocytosis and gastrointestinal stromal tumors.

What is bezuclastinib, and what conditions does it target?

Bezuclastinib is a selective tyrosine kinase inhibitor developed by Cogent, targeting the KIT D816V mutation linked to systemic mastocytosis and other mutations found in gastrointestinal stromal tumors.

Where is Cogent Biosciences headquartered?

Cogent Biosciences is headquartered in Waltham, Massachusetts, and Boulder, Colorado.